Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (311-320 of 397) with videos related to

Pageof 40
Sort By:
Plos One|December 1, 2017
A comprehensive analysis of breast cancer microbiota and host gene expressionKevin J Thompson, James N Ingle, Xiaojia Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Nature Communications|May 21, 2026
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase CβAnh T Q Cong, Taylor L Witter, Elizabeth S Bruinsma, et al.
Breast Cancer Research and Treatment|April 22, 2017
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathwayTanda M Dudenkov, James N Ingle, Aman U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle, Daniel J Schaid, Paul E Goss, et al.
BMC Cancer|October 8, 2014
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancerJordan M Reese, Vera J Suman, Malayannan Subramaniam, et al.
Clinical Breast Cancer|November 8, 2024
Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic ExperienceNusrat Jahan, Jodi Taraba, Nicholas J Boddicker, et al.
NPJ Breast Cancer|December 19, 2023
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancerSwaathi Jayaraman, Xinyan Wu, Krishna R Kalari, et al.
Breast Cancer Research and Treatment|November 23, 2006
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenMatthew P Goetz, Stacey K Knox, Vera J Suman, et al.
JAMA|October 8, 2009
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenWerner Schroth, Matthew P Goetz, Ute Hamann, et al.
Pageof 40

Showing results (311-320 of 397) with videos related to

Sort By:
Pageof 40
Plos One|December 1, 2017
A comprehensive analysis of breast cancer microbiota and host gene expressionKevin J Thompson, James N Ingle, Xiaojia Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.
Nature Communications|May 21, 2026
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase CβAnh T Q Cong, Taylor L Witter, Elizabeth S Bruinsma, et al.
Breast Cancer Research and Treatment|April 22, 2017
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathwayTanda M Dudenkov, James N Ingle, Aman U Buzdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle, Daniel J Schaid, Paul E Goss, et al.
BMC Cancer|October 8, 2014
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancerJordan M Reese, Vera J Suman, Malayannan Subramaniam, et al.
Clinical Breast Cancer|November 8, 2024
Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic ExperienceNusrat Jahan, Jodi Taraba, Nicholas J Boddicker, et al.
NPJ Breast Cancer|December 19, 2023
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancerSwaathi Jayaraman, Xinyan Wu, Krishna R Kalari, et al.
Breast Cancer Research and Treatment|November 23, 2006
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenMatthew P Goetz, Stacey K Knox, Vera J Suman, et al.
JAMA|October 8, 2009
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenWerner Schroth, Matthew P Goetz, Ute Hamann, et al.
Pageof 40